Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + iberdomide + dexamethasone in elderly patients with multiple myeloma at first relapse
2024-516257-44-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide, ixazomib and dexamethasone in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Very good partial response or better rate. Planned start Nov 2024; status: authorised.
02
Drugs
iberdomideixazomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516257-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516257-44-00.